Simulating 1-D Amyloid Co- polymerization KSU REU Noeloikeau Charlot Dr. Jeremy Schmit Dr. Chris Sorensen

Introduction ● Amyloid : polypeptides which polymerize to form cross-beta structures ● Co-polymer : a polymer consisting of two or more monomers (subunits) The objective of this project is to simulate a one-dimensional amyloid copolymer consisting of two subunits: IAPP (amylin) and Aβ (amyloid beta). IAPP is secreted alongside insulin and has been linked to type-II diabetes. Aβ is the main component of amyloid plaques associated with Alzheimer’s. This project builds on work done by Sheena Radford (2017) on IAPP/Aβ amyloid copolymerization, and explores the case in which binding between dissimilar subunits is stronger than binding between similar subunits.

2 Molecules, 3 Possible Chains and Reactions ● Two molecules, A & B ● Form linear chain ABAABABBABBAABAAAB… ● Can form Alternating, Block, or Random sequence ● Type depends on interaction energies: E ij ● Let I denote the last position in the chain ● Possible reactions: …I→...IA, …I→...IB, …I→..(I -1)

Algorithm Randomizes Reactions and Timesteps ● Let K 1 be reaction rate for addition of A ● Let K 2 be reaction rate for addition of B ● Let K 3 ∝ exp(-E ij ) be reaction rate for last element removal ● Let K tot = K 1 +K 2 +K 3 1. Generate random number: 0<R 1 <1 2. If: { R 1 ≤K 1 /K tot : add A to chain ; R 1 ≤(K 1 +K 2 )/K tot : add B ; else remove } 3. Generate random number: 0<R 2 <1 4. Update timestep defined by: t+= -ln(1-R 2 )/K tot

Parameter Space Consists of Concentration C, Binding Energy E, and Composition of Solution P ● Define order parameter: M = ( L ) -1 ∑ s i from i=1 to i=L where ● s = {-1: A ; +1: B } and L = length of chain M can be thought of as the composition of the aggregate polymer, and we observe changes in M by varying: ● Concentration: C ● Binding Energy: E ● Ratio of A to B: P P can also be thought of as the composition of the solution.

E=1: Composition of Aggregate Determined by Composition of Solution High Concentrations: ● M ≈ P Low Concentrations: ● M ≈ P ⇒ Linear.

E=1: Level Sets of P Observed in (M,C) Plane P=0.9 P=0.1

E=5: Composition of Aggregate Determined by Binding Energy at Low Concentrations High Concentrations ● M ≈ P Low Concentrations ● M ≈ constant ⇒ Sigmoidal.

E=5: Level Sets of P Observed in (M,C) Plane P=0.9 P=0.1

Recap: Composition of Aggregate is a Function of Energy and Concentration Small E : ● Composition of aggregate determined by composition of solution. ● Independent of concentration. Large E : ● Composition of aggregate depends on composition of solution only at high concentrations. ● At low concentrations, it is determined by the binding energy. Now let’s look at growth rate “ ”...

E=1: Growth Rate Independent of P ● Symmetric case: indistinguishable particles ● G ~ constant ● Different curves of P indistinguishable

E=2: Growth Rate Largest Closest to P=0.5 P= 0.6, 0.4 P= 0.5 P= 0.9, 0.1 ● Symmetry broken ● G ~ P ● Values of P closest to 0.5 show highest growth rate ● Chain alternates between A and B, maximizing number of strong bonds and minimizing number of off events

E=5: Growth Rate Begins at Lower Concentration P= 0.6, 0.4 P= 0.5 P= 0.9, 0.1 ● High asymmetry ● As E increases, G becomes nonzero at lower values of C ● This is because, at low concentrations, the stronger binding energy allows bonds between different types to persist in the time between addition events ● Hence we would expect the value of M to be zero in this region, which is precisely what was observed earlier

Growth Starts at Lower Concentrations for Higher Energies

Summary & Future Research ● At high concentrations, chain constituency determined by concentration. ● At low concentrations, chain constituency determined by binding energy. ● Chains with high binding energies begin growing at lower concentrations. ● Future research could account for different masses, charge, and structure.

Protein polymerization simulation for amyloid diseases (Prion, Alzheimer s)

Novel Treatment Strategies for Patients With Heart Failure Diagnosis and

How to change and monitor the rates of A amyloid accumulation and cognitive

Brochure Brochure More information from

Persistence of BAN2401-Mediated Amyloid Reductions Post-Treatment: A

ECH polymerization Qualification of a solvent compatible with REACh

High Performance Research Computing Simulating Chromosome Segregation Qi

Simulating Syst Simulating Systems in Gr ems in Ground V ound Vehicle hicle

On The Asymptotic Distribution of Nucleation Times of Polymerization

18 TH INTERNATIONAL CONFERENCE ON COMPOSITE MATERIALS EFFECTS OF

J Cancer Sci Clin Ther 2018; 2 (4): 089-091 DOI: 10.26502/jcsct.5079011 Case

Long-term safety and efficacy of AG10 in ATTR-CM: Phase 2 Open Label

To Fold or to Misfold: What is the Problem? (Molecular Origami) Sheena E

Progress in detecting prions and diagnosing prion diseases Byron Caughey

Variable Presentation and Pathologic Overlap of Rare Neuromuscular Condition

Case Report Ear, Nose & Throat Journal 14 A Rare Nasopharyngeal

2/27/2014 Disclosures for Ann McNeill Consultant / Advisor for Celgene

#O226 Genome-wide longitudinal analysis of emm1 invasive Group A Streptococcus

EU regulatory perspective on the potential use of biomarkers in AD drug

Developing Xanamem Presented by, Dr. Bill Ketelbey CEO & Managing

COR388, A NOVEL GINGIPAIN INHIBITOR, DECREASES FRAGMENTATION OF APOE IN

Severely Debilitating or Life- Threatening Hematologic Diseases John